Company overview
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing GANX with another company.
| Daily close (USD) | $1.62 |
| Market capitalization (USD) | $70,484,444.69 |
| Price / earnings (TTM) | Not reported |
| Price / book | 6.24 |
No matching rows. Clear the filter to see all records.
Read GANX's valuation metrics
Company size
Gain Therapeutics, Inc. Common Stock's recorded market capitalization is $70,484,444.69. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
GANX's recorded price-to-book ratio is 6.24. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Gain Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about GANX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow GANX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.